Categories: Healthcare

(2024-2033) Self-Administered Parenteral Market Size, Share, Trends, Industry Growth Analysis and Forecast | Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., AstraZeneca PLC

Overview and Scope
Self-administered parenteral refers to the administration of medication or substances into the body by oneself through injection methods. This method provides patients with greater autonomy and convenience, allowing them to manage the conditions in a more flexible and comfortable environment without the need for frequent visits to healthcare facilities.

Sizing and Forecast
The self-administered parenteral market size has grown strongly in recent years. It will grow from $23.14 billion in 2023 to $24.57 billion in 2024 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to rise in chronic diseases, aging population, government initiatives, patient education and support programs, the rising incidences of bone disorders.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/self-administered-parenteral-global-market-report

Segmentation & Regional Insights
The self-administered parenteral market covered in this report is segmented –

1) By Product: Pre-Filled Syringes, Autoinjectors, Pen Injectors, Other Products
2) By Usage: Disposable, Reusable
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Home Healthcare Providers, Specialty Clinics, Other Distribution Channels
4) By Application: Cardiovascular Diseases, Diabetes, Osteoporosis, Pain Management, Hormone Replacement, Other Applications

North America was the largest region in the self-administered parenteral market in 2023. The regions covered in the self-administered parenteral market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13927&type=smp

Major Driver Impacting Market Growth
The growing incidence of chronic diseases is expected to propel the growth of the self-administered parenteral market going forward. Chronic diseases are long-lasting medical conditions that generally progress slowly over time and often require ongoing management and treatment. Self-administered parenteral products are used in the management of chronic diseases to manage treatment independently, which can significantly improve adherence compared to oral medication. For instance, in January 2023, according to the National Institutes of Health, a US-based government agency, among the population aged 50 or above, the number of people with at least one chronic disease is expected to increase by 99.5% from 71.522 million in 2020 to 142.66 million by 2050. Therefore, the growing incidence of chronic diseases is driving the growth of the self-administered parenteral market.

Key Industry Players
Major companies operating in the self-administered parenteral market report are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., AstraZeneca PLC, Roche Holding AG, Eli Lilly and Company, Novo Nordisk A/S, Becton, Dickinson and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Terumo Corporation, Catalent Inc., Dexcom Inc., West Pharmaceutical Services Inc., Gerresheimer AG, Biocon Limited, Insulet Corporation, Halozyme Therapeutics Inc., Ypsomed AG, Antares Pharma Inc., SHL Medical AG, Owen Mumford Ltd., Novartis AG, Kaleo Inc., Haselmeier AG, Bespak (A Consort Medical Company), Senseonics Holdings Inc., ScPharmaceuticals Inc., Fresenius Kabi AG

The self-administered parenteral market report table of contents includes:

1. Executive Summary

2. Self-Administered Parenteral Characteristics

3. Self-Administered Parenteral Trends And Strategies

4. Self-Administered Parenteral – Macro Economic Scenario

5. Global Self-Administered Parenteral Size and Growth

…..

32. Global Self-Administered Parenteral Competitive Benchmarking

33. Global Self-Administered Parenteral Competitive Dashboard

34. Key Mergers And Acquisitions In The Self-Administered Parenteral

35. Self-Administered Parenteral Future Outlook and Potential Analysis

36. Appendix